questionText: To ask the Secretary of State for Health and Social Care, how many multiple myeloma patients have been treated with isatuximab in combination with pomalidomide and dexamethasone under the Cancer Drugs Fund; and if she will make an assessment of the potential impact of loss of access to this therapy on patients.
answerText: Isatuximab, in combination with pomalidomide and dexamethasone, has been available via the Cancer Drugs Fund (CDF) since October 2020. To date, 1,703 patients have been registered to start treatment.The National Institute for Health and Care Excellence (N...
heading: Multiple Myeloma: Drugs